Table of Contents Author Guidelines Submit a Manuscript
Current Gerontology and Geriatrics Research
Volume 2008, Article ID 858759, 7 pages
http://dx.doi.org/10.1155/2008/858759
Clinical Study

IDE Gene Polymorphism Influences on BPSD in Mild Dementia of Alzheimer's Type

1Department of Neuropsychiatry, Hyogo College of Medicine, Hyogo 663-8501, Japan
2Kaede Cocorono Hospital, Osaka 598-0002, Japan

Received 7 March 2008; Revised 14 July 2008; Accepted 3 October 2008

Academic Editor: George Kuchel

Copyright © 2008 Noriko Sato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Donaldson, N. Tarrier, and A. Burns, “The impact of the symptoms of dementia on caregivers,” British Journal of Psychiatry, vol. 170, no. 1, pp. 62–68, 1997. View at Publisher · View at Google Scholar
  2. I. V. Kurochkin and S. Goto, “Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme,” FEBS Letters, vol. 345, no. 1, pp. 33–37, 1994. View at Publisher · View at Google Scholar
  3. W. Q. Qiu, D. M. Walsh, Z. Ye et al., “Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation,” The Journal of Biological Chemistry, vol. 273, no. 49, pp. 32730–32738, 1998. View at Publisher · View at Google Scholar
  4. K. Vekrellis, Z. Ye, W. Q. Qiu et al., “Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme,” The Journal of Neuroscience, vol. 20, no. 5, pp. 1657–1665, 2000. View at Google Scholar
  5. W. Farris, S. Mansourian, Y. Chang et al., “Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4162–4167, 2003. View at Publisher · View at Google Scholar · View at PubMed
  6. H. Akiyama, K. Yokono, K. Shii et al., “Natural regulatory mechanisms of insulin degradation by insulin degrading enzyme,” Biochemical and Biophysical Research Communications, vol. 170, no. 3, pp. 1325–1330, 1990. View at Publisher · View at Google Scholar
  7. W.-L. Kuo, A. G. Montag, and M. R. Rosner, “Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues,” Endocrinology, vol. 132, no. 2, pp. 604–611, 1993. View at Publisher · View at Google Scholar
  8. F. Authier, B. I. Posner, and J. J. M. Bergeron, “Insulin-degrading enzyme,” Clinical and Investigative Medicine, vol. 19, no. 3, pp. 149–160, 1996. View at Google Scholar
  9. C. J. Groves, S. Wiltshire, D. Smedley et al., “Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility,” Diabetes, vol. 52, no. 5, pp. 1300–1305, 2003. View at Publisher · View at Google Scholar
  10. S. Karamohamed, S. Demissie, J. Volcjak et al., “Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study,” Diabetes, vol. 52, no. 6, pp. 1562–1567, 2003. View at Publisher · View at Google Scholar
  11. G. J. Biessels, S. Staekenborg, E. Brunner, C. Brayne, and P. Scheltens, “Risk of dementia in diabetes mellitus: a systematic review,” Lancet Neurology, vol. 5, no. 1, pp. 64–74, 2006. View at Publisher · View at Google Scholar · View at PubMed
  12. D. G. Cook, J. B. Leverenz, P. J. McMillan et al., “Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele,” The American Journal of Pathology, vol. 162, no. 1, pp. 313–319, 2003. View at Google Scholar
  13. L. Bertram, D. Blacker, K. Mullin et al., “Evidence for genetic linkage Alzheimer's disease to chromosome 10q,” Science, vol. 290, no. 5500, pp. 2302–2303, 2000. View at Publisher · View at Google Scholar · View at PubMed
  14. N. Ertekin-Taner, N. Graff-Radford, L. H. Younkin et al., “Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees,” Science, vol. 290, no. 5500, pp. 2303–2304, 2000. View at Publisher · View at Google Scholar · View at PubMed
  15. A. Myers, P. Holmans, H. Marshall et al., “Susceptibility locus for Alzheimer's disease on chromosome 10,” Science, vol. 290, no. 5500, pp. 2304–2305, 2000. View at Publisher · View at Google Scholar · View at PubMed
  16. S. D. Edland, F. Wavrant-De Vriesé, D. Compton et al., “Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE),” Neuroscience Letters, vol. 345, no. 1, pp. 21–24, 2003. View at Publisher · View at Google Scholar
  17. L. Bian, J. D. Yang, T. W. Guo et al., “Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese,” Neurology, vol. 63, no. 2, pp. 241–245, 2004. View at Google Scholar
  18. P. Nowotny, A. L. Hinrichs, S. Smemo et al., “Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme,” American Journal of Medical Genetics Part B, vol. 136B, no. 1, pp. 62–68, 2005. View at Publisher · View at Google Scholar · View at PubMed
  19. J. C. Mueller, M. Riemenschneider, A. Schoepfer-Wendels et al., “Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures,” Neurobiology of Aging, vol. 28, no. 5, pp. 727–734, 2007. View at Publisher · View at Google Scholar · View at PubMed
  20. R. Abraham, A. Myers, F. Wavrant-DeVrieze et al., “Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease,” Human Genetics, vol. 109, no. 6, pp. 646–652, 2001. View at Publisher · View at Google Scholar · View at PubMed
  21. M. Boussaha, D. Hannequin, P. Verpillat, A. Brice, T. Frebourg, and D. Campion, “Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease,” Neuroscience Letters, vol. 329, no. 1, pp. 121–123, 2002. View at Publisher · View at Google Scholar
  22. S. D. Edland, “Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease,” Journal of Molecular Neuroscience, vol. 23, no. 3, pp. 213–217, 2004. View at Publisher · View at Google Scholar · View at PubMed
  23. A. Sakai, H. Ujike, K. Nakata et al., “No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population,” American Journal of Medical Genetics Part B, vol. 125B, no. 1, pp. 87–91, 2004. View at Publisher · View at Google Scholar · View at PubMed
  24. E. Cellini, S. Bagnoli, A. Tedde, B. Nacmias, S. Piacentini, and S. Sorbi, “Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 19, no. 4, pp. 246–247, 2005. View at Publisher · View at Google Scholar
  25. A. Ozturk, S. T. DeKosky, and M. I. Kamboh, “Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease,” Neuroscience Letters, vol. 406, no. 3, pp. 265–269, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. L. Marlowe, R. Peila, K. S. Benke et al., “Insulin-degrading enzyme haplotypes affect insulin levels but not dementia risk,” Neurodegenerative Diseases, vol. 3, no. 6, pp. 320–326, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. B. Reisberg, “Dementia: a systematic approach to identifying reversible causes,” Geriatrics, vol. 41, no. 4, pp. 30–46, 1986. View at Google Scholar
  28. I. Gélinas, L. Gauthier, M. McIntyre, and S. Gauthier, “Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia,” American Journal of Occupational Therapy, vol. 53, no. 5, pp. 471–481, 1999. View at Google Scholar
  29. P. R. Wenham, W. H. Price, and G. Blundell, “Apolipoprotein E genotyping by one-stage PCR,” The Lancet, vol. 337, no. 8750, pp. 1158–1159, 1991. View at Publisher · View at Google Scholar
  30. B. Reisberg, E. Franssen, S. G. Sclan, A. Kluger, and S. H. Ferris, “Stage specific incidence of potentially remediable behavioral symptoms in aging and alzheimer disease. A study of 120 patients using the BEHAVE-AD,” Bulletin of Clinical Neurosciences, vol. 54, pp. 95–112, 1989. View at Google Scholar
  31. N. Scarmeas, J. Brandt, M. Albert et al., “Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease,” Neurology, vol. 58, no. 8, pp. 1182–1188, 2002. View at Google Scholar
  32. B. Reisberg, J. Borenstein, S. P. Salob, S. H. Ferris, E. Franssen, and A. Georgotas, “Behavioral symptoms in Alzheimer's disease: phenomenology and treatment,” The Journal of Clinical Psychiatry, vol. 48, pp. 9–15, 1987. View at Google Scholar
  33. W. E. Haley and K. M. Pardo, “Relationship of severity of dementia to caregiving stressors,” Psychology and Aging, vol. 4, no. 4, pp. 389–392, 1989. View at Publisher · View at Google Scholar
  34. W. Y. W. Mok, L. W. Chu, C. P. Chung, N. Y. Chan, and S. L. Hui, “The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease,” International Journal of Geriatric Psychiatry, vol. 19, no. 11, pp. 1040–1046, 2004. View at Publisher · View at Google Scholar · View at PubMed
  35. M. M. Bassiony and C. G. Lyketsos, “Delusions and hallucinations in Alzheimer's disease: review of the brain decade,” Psychosomatics, vol. 44, no. 5, pp. 388–401, 2003. View at Publisher · View at Google Scholar
  36. N. Hirono, E. Mori, K. Ishii et al., “Frontal lobe hypometabolism and depression in Alzheimer's disease,” Neurology, vol. 50, no. 2, pp. 380–383, 1998. View at Google Scholar
  37. D. E. Kuhl, E. J. Metter, W. H. Riege, and R. A. Hawkins, “The effect of normal aging on patterns of local cerebral glucose utilization,” Annals of Neurology, vol. 15, pp. 133–137, 1984. View at Publisher · View at Google Scholar
  38. P. J. Goodnick, J. H. Henry, and V. M. V. Buki, “Treatment of depression in patients with diabetes mellitus,” The Journal of Clinical Psychiatry, vol. 56, no. 4, pp. 128–136, 1995. View at Google Scholar
  39. P. J. Goodnick, “Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy,” Annals of Clinical Psychiatry, vol. 13, no. 1, pp. 31–41, 2001. View at Publisher · View at Google Scholar
  40. E. Holsboer-Trachsler, U. Hemmeter, U. von Bardeleben et al., “Neuroendocrine factors in neurodegenerative and cognitive disorder,” International Academy for Biomedical and Drug Research, vol. 7, pp. 180–186, 1994. View at Google Scholar